These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34641563)

  • 1. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.
    Aljanabi R; Alsous L; Sabbah DA; Gul HI; Gul M; Bardaweel SK
    Molecules; 2021 Oct; 26(19):. PubMed ID: 34641563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.
    Ramesh M; Muthuraman A
    Comb Chem High Throughput Screen; 2020; 23(9):887-897. PubMed ID: 32208114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
    Duarte P; Cuadrado A; León R
    Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A second life for MAO inhibitors? From CNS diseases to anticancer therapy.
    Sblano S; Boccarelli A; Mesiti F; Purgatorio R; de Candia M; Catto M; Altomare CD
    Eur J Med Chem; 2024 Mar; 267():116180. PubMed ID: 38290352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
    Deshwal S; Di Sante M; Di Lisa F; Kaludercic N
    Curr Opin Pharmacol; 2017 Apr; 33():64-69. PubMed ID: 28528298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure-Activity Relationships Predictive Models.
    Mladenović M; Patsilinakos A; Pirolli A; Sabatino M; Ragno R
    J Chem Inf Model; 2017 Apr; 57(4):787-814. PubMed ID: 28291352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of β-carboline and its derivatives as selective MAO-A inhibitors.
    Benny F; Kumar S; Jayan J; Abdelgawad MA; Ghoneim MM; Kumar A; Manoharan A; Susan R; Sudevan ST; Mathew B
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300091. PubMed ID: 37021551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined 3D-QSAR and docking analysis for the design and synthesis of chalcones as potent and selective monoamine oxidase B inhibitors.
    Mellado M; González C; Mella J; Aguilar LF; Viña D; Uriarte E; Cuellar M; Matos MJ
    Bioorg Chem; 2021 Mar; 108():104689. PubMed ID: 33571810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
    Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
    Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidases in development.
    Wang CC; Billett E; Borchert A; Kuhn H; Ufer C
    Cell Mol Life Sci; 2013 Feb; 70(4):599-630. PubMed ID: 22782111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders.
    Srivastava P; Sudevan ST; Thennavan A; Mathew B; Kanthlal SK
    CNS Neurol Disord Drug Targets; 2024; 23(3):331-341. PubMed ID: 36872357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors.
    Saha M; Gupta S; Dhiman S; Asati V; Ali A; Ali A
    J Biomol Struct Dyn; 2023; 41(21):12171-12185. PubMed ID: 36650997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective MAO-B inhibitors: a lesson from natural products.
    Carradori S; D'Ascenzio M; Chimenti P; Secci D; Bolasco A
    Mol Divers; 2014 Feb; 18(1):219-43. PubMed ID: 24218136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases.
    Shi R; Wu Q; Xin C; Yu H; Lim KL; Li X; Shi Z; Zhang CW; Qian L; Li L; Huang W
    Chembiochem; 2019 Jun; 20(12):1487-1497. PubMed ID: 30664830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel monoamine oxidase selective inhibitors employing a hierarchical ligand-based virtual screening strategy.
    Wang D; Li Z; Liu Y; Chen M; Chen N; Zuo Z; Kong DX
    Future Med Chem; 2019 Apr; 11(8):801-816. PubMed ID: 31140884
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics, mechanism, and inhibition of monoamine oxidase.
    Ramsay RR; Albreht A
    J Neural Transm (Vienna); 2018 Nov; 125(11):1659-1683. PubMed ID: 29516165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor design for monoamine oxidases.
    Ramsay RR
    Curr Pharm Des; 2013; 19(14):2529-39. PubMed ID: 23116392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
    Bortolato M; Chen K; Shih JC
    Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs.
    Concu R; González-Durruthy M; Cordeiro MNDS
    Curr Top Med Chem; 2020; 20(18):1593-1600. PubMed ID: 32493193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.